In this video, Dr. Gregory Reaman gives an overview of childhood cancer survivorship and the importance of follow-up care after treatment is complete.

One in six children diagnosed with cancer in the United States lives in poverty, and despite uniform treatment in clinical trials, poverty-exposed children are more likely to relapse compared to children who are not exposed to poverty. Dana-Farber Cancer Institute seeks to improve childhood cancer outcomes by investigating poverty as a risk factor for relapse and developing novel poverty-targeted interventions. Listen to a presentation from Dana-Farber’s Kira Bona, MD, MPH, about her lab’s work to identify and alleviate poverty-associated outcome disparities in childhood cancers. The event is hosted by Joanne Wolfe, MD, MPH.

Dr. Jay Storm is a neurosurgeon at The Children's Hospital of Philadelphia. He operated on the brain tumors of two of the 2013 Parkway Run & Walk ambassadors, Mary and Naya.

In 2013, more than 10,000 children will be diagnosed with cancer, and about 1,500 will die from their disease. And although survival rates for many childhood cancers have improved dramatically over the past few decades, cancer is still the second leading cause of death in children.

Clinical trials for childhood cancer are among the fastest and safest ways to find treatments that work against these diseases. Philanthropic support is critical to funding ongoing research by our childhood cancer experts, and helping cover the costs of enrolling children on experimental therapies.

Watch as Dr. Storm discusses why it's critical that we spread the word about the need for childhood cancer research funding.

Childhood cancer is not an individual disease. It affects the whole family, community and society. On Wednesday, April 24, 2013, Lauren was diagnosed with Ewing Sarcoma. November 24th was her last day of chemo. Due to her cancer diagnosis and the drugs used to combat the cancer, Lauren will have to be monitored for late effects for the rest of her life.

Knowing the long-term implications is invaluable for families; it gives them an element of control and highlights things they should be on the lookout for. The information POGO has gathered over 30+ years is helping Lauren now. And the information POGO is gathering now, from Lauren and other pediatric oncology patients, will inform Lauren’s doctors in the future. It’s always evolving.

The FDA Oncology Center of Center of Excellence presents Conversations on Cancer - The Future of Childhood Cancer Drug Development: Is the Sky the Limit? Join this 1 ½ hour informal panel discussion exploring personal perspectives from survivors, clinicians, caregivers, and pediatric patient advocates on the impact of childhood cancer.